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Parkin son 's dis ease is a slowl y progr essive, neurodegenerative di sorde r a ffec t ing one in 1,000 of th e gen eral p opulation ; its in cid e nce increases with age , but the ca use remains unknown . The di sease is characte r ized patho logicall y by a loss of neurons fr om th e pigmented su bs ta n t ia ni gra pa r s co mpacta , and a tr iad of ph ysical sym p to ms of rigidity, tremor, a nd b radykin esia or akinesia . T h us t he clini cal co nd itio n of Parkinson's di sease is a rat her com plex disorder with a variety of ph ysical sym p to ms due to neuronal dam age in a n um ber o f brain regi ons. Additional brain regions a lso affec te d in clinical Parkinson 's di sease include the ve n tra l te gmental a rea, locu s coer u leus, serotonergic dorsal raph e syste m, and th e d orsal motor nucleus of th e vagus ( I) . Furth ermore, it h as bee n suggeste d th at d amage to these var io us regions of th e b ra in leads to a vari ety o f motor and m ental di sorders (depression a nd d ementia) that are specific to th e dam ag e in eac h o f th ese neuronal syste ms (2) . Loss of no rep in e p h r ine may lea d to d epression ; the in cidence of d epr ession va r ies b e t wee n 20 to 90 percent in Parkinson 's di sea se, and many o f th ese patients show favorab le responses to tricyclic antidepressants.
Rec entl y, se ve ral individuals developed a Parkinson-like d iso r d e r followin g intravenous administration of MPTP ( l -methy l-4-p henyl -1,2,3,6-tetrah ydropyridine). MPTP is crea te d as a b yproduct in the syn t hesis of a synthetic heroi n l -m eth yl-4-ph en yl-4-propionoxypiperidine (M P P P). Ad m ixed with varying a m ou n ts of MPPP , MPTP was illicitly so ld as a n e w typ e o f h e r o in (3) in a lim ited region of northern California. Man y users d e vel oped a Parkinson-like disorde r with bradykin esia, rigidity, tremor, flexed po sture , los s of p ostu ral reflexes, an d drooling followin g intravenous administ ration of MPTP (3) (4) (5) . Results of M PTP us e in humans demonstrated that this co m pou nd ca n closely repr od uce th e sym p to ma to lo gy of idiopathic Parkinson's di sease, and may p r ovid e a new too l for in vestigating ba sic neurobiological and clinical aspects of Parkinson's disease, probabl y leading to bette r th erapeutic appr oach es th a n what has been a vail able so far.
MPTP AND PARKINSON'S DISEASE
A sev ere loss of pigmented nerve ce lls in the su bs ta n tia ni gra pa rs compact a and low levels of homovanillic ac id in the cerebrospinal fluid h a ve bee n re po rted 
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in patients with MPTP-induced Parkinsonism (4). The clinical sig ns and symptoms of Parkinsonism in th ese patients could be ameliorated by ad min istration of L-dopa (3,4) ; some patients experienced typical treatm ent-related co mp lications of long-term L-dopa therapy such as deterioration , peak-dose d yski nesia , and " o n-o ff " phenomena (5).
Furthermore, intravenous administration of MPTP ha s been repo rted to produce Parkinson-like sym p to ms in non-hum an primat es (6-8), inclu d ing bradykinesia, postural tremor, and muscular rigidity; L-dopa th erap y ameliorates these problems (6) . MPTP treatment resulted in d ecreased rel ease of dopamine in the striatum, and dopamine accumulation in swo lle n axons in the nigrostriatal pathway just rostral to the substantia nigra (6 ,9, I 0), foll owed by extensive loss of nerve cells in the pars compacta of th e su bs ta n tia nigra ( I I), and a marked reduction in the dopamine contents of th e striatum. MPTP has been also shown to produce degeneration of the nigrostriatal dopam inergic syste m in mice (12, 13) , as well as other monoaminergic systems (1 3 ,14) .
In humans, dopamine levels in the striatum decrease with age (15), bu t the decrease is much sharper in humans with Parkinson's di sease (16) . McG ee r a nd colleagues (17) showed that su bsta nt ia nigra neurons diminish in number wit h age , and may demonstrate qualitative differences in a p peara nce as well , suc h as sh r ive ling . These studies suggest that dopamine neurons undergo age-related changes that lead to diminished levels and syn t hesis of d opamine in ne r ve terminals, accompanied b y ce ll loss in th e su bsta n t ia nigra. More rec ently, it has been shown that MPTP giv en to aging mice produces more se vere ph ysica l an d morphological alterations (18) that are not seen in yo u ng ad u lt mice . The ph ysical symptoms include bradykinesia, rigidity, and a n initial resting t remor of th e whole body. Neuroanatomically, there is evid ence of changes in th e ventral tegemental area (mesolimbic dopaminergic system that se nds d opami ne p roj ections to the nucleus accumbens and the olfactory tubercle , i.e., th e limbic system) as well as the locus coeruleus (noradrenergic cell group that se nds proj ect io ns to the cerebral cortex, cerebellum, and hippocampus). All th ese st ud ies suggest that MPTP-induced animal models in non-human primates and m ice may provide insight into the mechanism and cause of neuronal degeneration.
MPTP AND MAO INHIBITORS
The oxidative metabolism of MPTP to its l-meth yl-4-ph enyl pyridinium analog (MPP+) is a critical feature in the neurotoxic process (19) . Furthe rm o re , th e monoamine oxidase (MAO) inhibitor, pargyline, and th e specific MAO-B inhibitors (deprenil, AGN-1133, AGN-1135), can prevent the conversio n of MPTP to MPP+, while the spec,ific MAO-A inhibitor, c1orgylin e , ha s no suc h effect (20) (21) (22) (23) (24) . These observations suggest that MAO-B is responsible fo r th e oxidative metabolism of MPTP to its p yridinium analog. More recently, using monoclonal antibodies to MAO-A and MAO-B in non-human primates, West-lund, et al (25) reported MAO-A positive cell bodies in neuro ns of ca techo lamine cell groups, whi le MAO-B cell bodies were observed in seroto nergic raph e nuclei, including raphe dorsalis a nd nucleus ce n t ra lis super ior. T hese findings suggest that MPTP ma y be taken up into serotonergic neurons, metabo lized to MPP +, released, and furth er tak en up by th e nigrostriatal a nd th e ventra l tegmental area dopaminergic syst ems, where damage to th ese neu rons then occurs.
